Floatz logo

CLOSTRIDIUM BUTYRICUM MIYAIRI 588

Parkinson Disease

Kaohsiung Medical University Chung-Ho Memorial Hospitalother_biologicalN/AActive
D
28/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
65/ 100

Competitive context

255 Active assets in the Parkinson Disease cohort.

Asset / SponsorPhaseRating
Safinamide
Zambon SpA
Phase 4A
Cvt-301
Acorda Therapeutics
Phase 3A
Istradefylline
Georgetown University
Phase 4BBB
Tvp-1012
Guangzhou Henovcom Bioscience Co. Ltd.
Phase 4BBB
Pardoprunox
Abbott Products
Phase 3BBB

View all 50 →

Same molecule, other indications

CLOSTRIDIUM BUTYRICUM MIYAIRI 588 is also rated in:

Metastatic Clear Cell Renal Cell CarcinomaDormant
BB
Indicative ·
70 / 100
View asset →
Stage IV Renal Cell Cancer AJCC v8Dormant
BB
Indicative ·
70 / 100
View asset →
nonpapillary renal cell carcinomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →